Unbound MEDLINE

SHORT-TERM EFFECTS OF THE LONG-ACTING INSULIN ANALOG DETEMIR AND HUMAN INSULIN ON PLASMA LEVELS OF INSULIN-LIKE GROWTH FACTOR-I AND ITS BINDING PROTEINS IN HUMANS. The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] Journal article

 
TitleSHORT-TERM EFFECTS OF THE LONG-ACTING INSULIN ANALOG DETEMIR AND HUMAN INSULIN ON PLASMA LEVELS OF INSULIN-LIKE GROWTH FACTOR-I AND ITS BINDING PROTEINS IN HUMANS.
Author(s)Porcellati F, Rossetti P, Candeloro P, Lucidi P, Cioli P, Andreoli AM, Ghigo E, Bolli GB, Fanelli CG 
InstitutionDepartment of Internal Medicine, Section of Internal Medicine, Endocrinology and Metabolism, University of Perugia, Perugia, Italy; Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Torino, Torino, Italy.
SourceJ Clin Endocrinol Metab 2009 May 26.
AbstractObjective: The objective of the study was to compare responses of plasma levels of IGF-I and IGF- binding proteins (IGFBP-1, -3) induced by human regular insulin (HI) and the long acting insulin analog detemir (IDet) at doses equivalent with respect to the glucose-lowering effect. Experimental design: Ten non-diabetic subjects (6 males, age 36+/-7 years, BMI 22.9+/-2.6 kg/m(2)) were studied on 4 randomized occasions, with i.v. infusion of IDet (2 mU/kg/min for 4h, followed by 4 mU/kg/min for 1h) or HI (1 mU/kg/min for 4h, followed by 2 mU/kg/min for 1h) in euglycemia (plasma glucose, PG, 90 mg/dl) or during stepped hypoglycemia (PG 90, 78, 66, 54, and 42 mg/dl).
Results: PG was maintained at pre-selected plateaus, without any significant difference between IDet and HI (p>0.2). Plasma insulin concentrations were on average approximately 9 times greater with IDet than HI (749+/-52 microU/ml vs 83+/-19 microU/ml, respectively). Plasma IGF-I concentrations did not change from baseline during insulin infusion in euglycemia (IDet 147+/-16, HI 155+/-15 ng/ml) and hypoglycemia (IDet 163+/-14, HI 165+/-14 ng/ml) with no differences between the two insulins (p>0.2). Similar pattern was observed for plasma IGFBP-3 levels. Insulin infusion resulted in a suppression of plasma IGFBP-1 concentrations with no differences between IDet (baseline 16.6+/-3.8, endpoint 2.0+/-0.6 ng/ml) and HI (baseline 16.6+/-4.1, endpoint 2.6+/-1.4 ng/ml) (p>0.2), and study conditions (p>0.2).
Conclusions: The greater plasma insulin concentrations obtained with IDet exert effects on plasma levels of IGF-I and IGFIBP-1 and IGFIBP-3 similar to those of HI. Additional studies are needed to confirm these short-term results in patients with diabetes mellitus, on long-term treatment with IDet.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19470629
  
Advertise on this site.